NCT00212641

Brief Summary

The objectives of this study are to characterize the pharmacodynamic profile, safety and tolerability of ONO-5129 in patients with Type 2 Diabetes mellitus

Trial Health

80
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
105

participants targeted

Target at P50-P75 for phase_2 diabetes-mellitus-type-2

Geographic Reach
1 country

67 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2005

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

September 12, 2005

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 21, 2005

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2007

Completed
Last Updated

October 11, 2012

Status Verified

October 1, 2012

Enrollment Period

2.3 years

First QC Date

September 12, 2005

Last Update Submit

October 10, 2012

Conditions

Outcome Measures

Primary Outcomes (1)

  • Fasting Blood Glucose at 8 weeks

Secondary Outcomes (1)

  • Pharmacodynamic parameters at all time points

Interventions

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 Diabetes Mellitus
  • FBG level \> 140 mg/dL and \< 270 mg/dL
  • Fasting TG level \< 500 mg/dL
  • BMI of 22 to 40 kg/m2, inclusive

You may not qualify if:

  • Previous participation in an ONO-5129 protocol
  • Previous treatment with TZD agents or other current antidiabetics
  • History of myocardial infarction, coronary artery surgery, atrial/ventricular tachycardia, or atrial/ventricular fibrillation in the past six months
  • Presence of functional limitations due to cardiovascular disease in accordance with the New York Heart Association Classification System - Class III (moderate) or IV (severe)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (67)

Apex Clinical Trials, Inc.

Birmingham, Alabama, 35209, United States

Location

Greystone Medical Research, LLC

Birmingham, Alabama, 35242, United States

Location

Med Search, LLC

Calera, Alabama, 35040, United States

Location

Medical Affiliated Research Center

Huntsville, Alabama, 35801, United States

Location

Clinic of Physicians and Surgeons

Mesa, Arizona, 85201, United States

Location

Horizon Clinical Research Associates

Mesa, Arizona, 85206, United States

Location

Cochise Clinical Research

Sierra Vista, Arizona, 85635, United States

Location

Sagebrush Medical Plaza, Department of Family Medicine

Bakersfield, California, 93305, United States

Location

Family Medical Center

Foothill Ranch, California, 92610, United States

Location

Prime-Care Clinical Research

Mission Viejo, California, 92691, United States

Location

Encompass Clinical Research

Spring Valley, California, 91978, United States

Location

Orange County Research Center

Tustin, California, 92780, United States

Location

Quality Care Medical Center

Vista, California, 92084, United States

Location

Arapahoe Internal Medicine

Littleton, Colorado, 80120, United States

Location

Institute Diabetes and Metabolic Disease

Newark, Delaware, 19713, United States

Location

Alliance Medical Reserach Group, Inc.

Clearwater, Florida, 33755, United States

Location

Personal Physician Care

Delray Beach, Florida, 33445, United States

Location

Century Clinical Research, Inc

Holly Hill, Florida, 32117, United States

Location

Innovative Research of West Florida

Largo, Florida, 33770, United States

Location

Cardiovascular Center of Sarasota

Sarasota, Florida, 34239, United States

Location

Executive Health and Research Associates, Inc.

Atlanta, Georgia, 30342, United States

Location

Capital City Family Medicine

Boise, Idaho, 83702, United States

Location

Orthopedic Health Care Clinic

Boise, Idaho, 83702, United States

Location

Sonora Clinical Research

Boise, Idaho, 83702, United States

Location

Cedar-Crosse Research Center

Chicago, Illinois, 60607, United States

Location

Chicago Research Center, Inc.

Chicago, Illinois, 60634, United States

Location

Heart of America Research

Shawnee, Kansas, 66216, United States

Location

Dolby Research, LLC

Baton Rouge, Louisiana, 70809, United States

Location

Acadia Clinical Research, LLC

Bangor, Maine, 04401, United States

Location

Franklin Square Hospital Center

Baltimore, Maryland, 21237, United States

Location

Centennial Medical Group

Elkridge, Maryland, 21075, United States

Location

Professional Clinical Reserach -Great Lakes Family Care

Cadillac, Michigan, 49601, United States

Location

Synergy Medical Education Alliance

Saginaw, Michigan, 48602, United States

Location

Medex Healthcare Research, Inc

St Louis, Missouri, 63108, United States

Location

Mercury Street Medical

Butte, Montana, 59701, United States

Location

Specialty Medical Center

Pahrump, Nevada, 89048, United States

Location

Bassett Healthcare

Cooperstown, New York, 13326, United States

Location

DiGiovanna Family Care Center

Great Neck, New York, 11021, United States

Location

United Physicians Group - Endocrine Division

Great Neck, New York, 11021, United States

Location

Winthrop University Hospital

Mineola, New York, 11501, United States

Location

New Horizons Clinical Research

Cincinnati, Ohio, 45252, United States

Location

Wells Institute for Health Awareness

Kettering, Ohio, 45429, United States

Location

Fallen Timbers Internal Medicine LLC

Maumee, Ohio, 43537, United States

Location

COR Clinical Reserch, LLC

Oklahoma City, Oklahoma, 73103, United States

Location

Cllinical Research Consultants

Medford, Oregon, 97504, United States

Location

Covance Clinical Research Unit, Inc

Portland, Oregon, 92739, United States

Location

Michael A. Azorr, M.D.

Portland, Oregon, 97232, United States

Location

Keystone Clinical Solutions

Altoona, Pennsylvania, 16602, United States

Location

Southeastern PA Medical Institute

Havertown, Pennsylvania, 19083, United States

Location

Greenand Seidner Family Practice

Lansdale, Pennsylvania, 19446, United States

Location

Thomas Jefferson University Div of Endocrinology

Philadelphia, Pennsylvania, 19107, United States

Location

Founders Medical Practice

Philadelphia, Pennsylvania, 19152, United States

Location

Research Endeavors

Pittsburgh, Pennsylvania, 15238, United States

Location

Hillcrest Clinical Research LLC

Simpsonville, South Carolina, 29681, United States

Location

Spartanburg Medical Research

Spartanburg, South Carolina, 29303, United States

Location

John Joseph, MD PA

Carrollton, Texas, 75007, United States

Location

Renaissance Clinical Research

Dallas, Texas, 75235, United States

Location

MCA Research

Houston, Texas, 77024, United States

Location

Southwest Houston Research, LTD

Houston, Texas, 77074, United States

Location

Professional for Clinical Research

Plano, Texas, 75093, United States

Location

Research Across America

Plano, Texas, 75093, United States

Location

Benjamin Garwood Research

San Antonio, Texas, 78216, United States

Location

WellMed at Northern Hills

San Antonio, Texas, 78217, United States

Location

Diabetes and Glandular Disease Research Associates

San Antonio, Texas, 78229, United States

Location

Diabetes and Glandular Disease - Westside office

San Antonio, Texas, 78237, United States

Location

Liberty Research Center

Tacoma, Washington, 98405, United States

Location

Hyperion Clinical Trials, Inc.

Charleston, West Virginia, 25304, United States

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Joseph G Bisaha, Ph.D.

    Ono Pharma USA Inc

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 21, 2005

Study Start

June 1, 2005

Primary Completion

October 1, 2007

Last Updated

October 11, 2012

Record last verified: 2012-10

Locations